MRD陰性化 – Medxy AI

Venetoclax Combined with Pediatric-Inspired Chemotherapy Enhances Outcomes in Adolescents and Adults with Ph-Negative Acute Lymphoblastic Leukemia

By MedXY 10/01/2026

A phase 2 trial demonstrates that adding venetoclax to pediatric chemotherapy regimens in adolescents and adults with newly diagnosed Philadelphia chromosome-negative ALL significantly improves MRD negativity and survival with manageable toxicity.

Hematology-Oncology news Oncology

Cytogenetic Insights into Multiple Myeloma Outcomes Despite MRD Negativity Post-Autologous Stem Cell Transplant

By MedXY 08/02/2026

This study reveals that certain high-risk cytogenetic abnormalities continue to influence progression-free survival in multiple myeloma patients even after achieving deep MRD negativity post-ASCT, highlighting the need for tailored post-transplant strategies.

Hematology-Oncology news

Slow but Steady: t(11;14) Myeloma Shows Superior Outcomes Despite Delayed MRD Negativity with Quadruplet Therapy

By MedXY 04/24/2026

t(11;14) multiple myeloma exhibits slower MRD clearance but superior PFS with quadruplet therapy and MRD-adapted management, challenging conventional response kinetics paradigms.